Pieris Pharmaceuticals (NASDAQ:PIRS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRSFree Report) in a research report report published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Trading Down 1.7 %

Pieris Pharmaceuticals stock opened at $0.17 on Friday. The firm’s 50 day simple moving average is $0.17 and its 200 day simple moving average is $0.24. The firm has a market capitalization of $16.31 million, a PE ratio of -0.47 and a beta of 0.51. Pieris Pharmaceuticals has a 1-year low of $0.14 and a 1-year high of $1.72.

Pieris Pharmaceuticals (NASDAQ:PIRSGet Free Report) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). The business had revenue of $19.52 million for the quarter, compared to analyst estimates of $7.74 million. Pieris Pharmaceuticals had a negative net margin of 59.25% and a negative return on equity of 98.12%. Research analysts forecast that Pieris Pharmaceuticals will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Pieris Pharmaceuticals

A number of institutional investors have recently made changes to their positions in PIRS. Tower Research Capital LLC TRC increased its holdings in shares of Pieris Pharmaceuticals by 9,665.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock worth $25,000 after buying an additional 21,360 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Pieris Pharmaceuticals by 50.0% in the 4th quarter. Raymond James & Associates now owns 30,000 shares of the biotechnology company’s stock worth $31,000 after buying an additional 10,000 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Pieris Pharmaceuticals in the 1st quarter worth $32,000. Mirabella Financial Services LLP bought a new position in shares of Pieris Pharmaceuticals in the 1st quarter worth $39,000. Finally, Two Sigma Investments LP bought a new position in shares of Pieris Pharmaceuticals in the 3rd quarter worth $43,000. Institutional investors own 75.03% of the company’s stock.

Pieris Pharmaceuticals Company Profile

(Get Free Report)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

See Also

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.